Ethical challenges in outbreak trial design: from Ebola to Nipah
Vaccine·
- DOI
- 10.1016/j.vaccine.2026.128858
- PMID
- 42470890
- PMCID
- —
- OpenAlex
- W7169668693
- Study type
- Journal article
- Publisher
- Elsevier BV
- Article type
- journal-article
- Integrity
- current
Why this research matters now
The discussion is relevant to accelerating ethically acceptable evaluation of Nipah and other outbreak vaccines, including the role of early and sustained community engagement across epidemic and inter-epidemic periods.
Structured evidence summary
Research question
The paper examines key ethical issues in designing vaccine trials for Nipah virus outbreaks, drawing broader lessons from outbreak trial experience with high-mortality pathogens such as Ebola.
Study design
The contribution is framed as an ethical analysis of trial-design considerations for outbreak settings, without a primary empirical protocol or trial reported.
Population and setting
The discussion is anchored to Nipah virus outbreak settings, where transmission is concentrated within households and healthcare facilities, with relevance to populations at high risk of infection during short-duration epidemics.
Main findings
The paper outlines trade-offs among trial designs for high-mortality outbreak pathogens: recruiting high-risk individuals is needed to reach efficacy endpoints, yet placebo controls can be controversial. It notes that cluster randomization may delay endpoints when transmission is concentrated in few clusters, delayed-vaccination designs may not meaningfully reduce risk for controls, and single-arm trials may fail to clarify efficacy. It also highlights tensions between high pre-trial efficacy probabilities and traditional equipoise, and calls for revised post-trial access policies for control participants.
Public-health relevance
The discussion is relevant to accelerating ethically acceptable evaluation of Nipah and other outbreak vaccines, including the role of early and sustained community engagement across epidemic and inter-epidemic periods.
Important limitations
The abstract does not enumerate explicit study limitations; this summary is limited to the supplied single-article abstract and bibliographic metadata and requires the original paper for decision-grade interpretation.
GIDS interpretation
The article is discoverable through its focus on Nipah outbreak trial design and on ethical and methodological considerations for vaccine evaluation in high-mortality, short-duration epidemics, providing context for future Nipah-related literature without being linked to a specific surveillance signal.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 13 auditable classifier relationships to diseases, places, topics, and study design.